Moleculin Biotech, Inc. Stock price

Equities

MBRX

US60855D3098

Pharmaceuticals

Market Closed - Nasdaq 04:00:00 2024-03-27 pm EDT 5-day change 1st Jan Change
5.54 USD +18.38% Intraday chart for Moleculin Biotech, Inc. -12.19% -56.97%
Sales 2024 * - Sales 2025 * - Capitalization 12.34M
Net income 2024 * -28M Net income 2025 * -31M EV / Sales 2024 * -
Net cash position 2024 * - Net cash position 2025 * - EV / Sales 2025 * -
P/E ratio 2024 *
-0.48 x
P/E ratio 2025 *
-0.68 x
Employees 18
Yield 2024 *
-
Yield 2025 *
-
Free-Float 95.35%
More Fundamentals * Assessed data
Dynamic Chart
1 day+18.38%
1 week-12.19%
Current month-41.28%
1 month-40.04%
3 months-47.98%
6 months-8.78%
Current year-56.97%
More quotes
1 week
4.34
Extreme 4.34
6.24
1 month
4.34
Extreme 4.34
10.35
Current year
4.34
Extreme 4.34
15.75
1 year
4.34
Extreme 4.34
24.75
3 years
4.34
Extreme 4.34
71.55
5 years
4.34
Extreme 4.34
283.50
10 years
4.34
Extreme 4.34
862.20
More quotes
Managers TitleAgeSince
Founder 78 15-07-27
Chief Executive Officer 64 15-07-27
Director of Finance/CFO 60 16-08-21
Members of the board TitleAgeSince
Chief Executive Officer 64 15-07-27
Director/Board Member 78 15-06-30
Director/Board Member 55 17-07-23
More insiders
Date Price Change Volume
24-03-27 5.54 +18.38% 89,261
24-03-26 4.68 -10.86% 92,008
24-03-25 5.25 -7.97% 915,721
24-03-22 5.705 -13.96% 98,642
24-03-21 6.63 +5.09% 44,752

Delayed Quote Nasdaq, March 27, 2024 at 04:00 pm EDT

More quotes
Moleculin Biotech, Inc. is a clinical-stage pharmaceutical company. The Company has a pipeline of clinical programs for the treatment of tumors and viruses. It has three core technologies and six drug candidates, three of which have shown human activity in clinical trials. Its core technologies consist of Annamycin, WP1066 Portfolio and WP1122 Portfolio. Annamycin is designed to avoid multidrug resistance mechanisms and cardiotoxicity. Its WP1066 Portfolio (including lead drug candidates WP1066 and WP1220) represents a class of agents capable of hitting multiple targets, including the activated form of a key oncogenic transcription factor, STAT3. WP1066 is its flagship Immune/Transcription Modulator. An analog of WP1066, referred to as WP1220, is related to the use of the molecule in the topical treatment of psoriasis. Annamycin is in development for the treatment of refractory acute myeloid leukemia (AML) and soft tissue sarcoma (STS) lung metastases.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
-
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
3
Last Close Price
5.54 USD
Average target price
35 USD
Spread / Average Target
+531.77%
Consensus
  1. Stock
  2. Equities
  3. Stock Moleculin Biotech, Inc. - Nasdaq